Quest Diagnostics Insider Sold Shares Worth $5.48 Million
A recent SEC filing indicates that an insider at Quest Diagnostics Incorporated sold company shares valued at approximately $5.48 million.
Stocks · News reference
Rothschild & Co Redburn Adjusts Price Target on Quest Diagnostics to $279 From $251
Rothschild & Co Redburn has increased its price target for Quest Diagnostics Incorporated, moving it from $251 to $279.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
DOT Consortium Integrates with Quest Diagnostics for New Compliance Testing Packages
DOT Consortium has launched new return-to-duty and follow-up testing packages on its online compliance platform, which integrates with Quest Diagnostics' laboratory network.
Evercore ISI Adjusts Price Target on Quest Diagnostics to $240 From $235
Evercore ISI has updated its price target for Quest Diagnostics, raising it from $235 to $240.
Quest Diagnostics Reports Cyber Breach Affecting Quanum Lab Services Manager
Quest Diagnostics disclosed a cybersecurity incident involving unauthorized access to its Quanum Lab Services Manager platform, potentially impacting patient data.
Deutsche Bank Adjusts Quest Diagnostics Price Target to $245
Deutsche Bank has updated its price target for Quest Diagnostics, moving it from $232 to $245 while maintaining a 'Hold' rating.
Quest Diagnostics Bumps Guidance While Managing Quanum System Breach
Quest Diagnostics tops Q3 estimates, raises full-year 2026 guidance, and addresses an unauthorized Quanum LSM cybersecurity event.